Therapeutic effect of Sintilimab on recurrent non-small cell lung cancer

LV Tong-shuai; YANG Fan; YANG Wei; GOU Xiao-hua; WANG Xiang-na

doi:10.3969/j.issn.1672-8157.2023.06.001

Abstract：Objective:To investigate the therapeutic efficacy of sintilimab for recurrent non-small cell lung cancer(R-NSCLC).Methods:The clinical data of 153 patients with R-NSCLC admitted to our hospital from January 2019 to January 2019 were retrospectively analyzed.Patients were assigned into two groups according to different treatment plans.The patients in control group(n=74)recieved intravenous infusion of cisplatin 50 mg·m-2 on day 1 and that of gemcitabine 1000 mg·m-2 on day 2 or 3.The patients in the experimental group undergoing intravenous infustion of sintilimab 200 mg on day 1 in addition to that in the control group.All patients were treated for 4 courses of treatment with 21d as 1 course.Then the clinical efficacy,serum tumour markers,immune function and treatment safety were compared between the 2groups.Results:Experimental group reported a higher objective remission rate and disease control rate as compared to control one(65.82%vs.50.00%,93.67%vs.82.43%,P<0.05).A reduction in cytokeratin fragment 19(CYFRA 21-1),carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA199),and an increase in peripheral blood CD3+,CD4+and CD4+/CD8+were observed in all patients after treatment,and both improvements were more notable in the experimental group than in the control(P<0.05).No statistical difference was reported in CD8+before and after chemotherapy between the 2 groups(P>0.05).The incidence of adverse reactions during treatment yielded no statistical difference between the 2 groups(P>0.05).Conclusion:Sintilimab is effective in treating patients with R-NSCLC,which can improve patients'immune function and significantly reduce serum levels of tumour markers.